Updates are available Correction dated 2022-03-10
Click to view Correction: https://doi.org/10.1007/s00259-022-05736-6
-
Authors
Krebs, Simone https://orcid.org/0000-0002-9909-4531
Grommes, Christian https://orcid.org/0000-0002-7485-0441
McDevitt, Michael R.
Carlin, Sean D.
O’Donoghue, Joseph A. https://orcid.org/0000-0002-2761-0015
Graham, Maya S. https://orcid.org/0000-0003-4748-974X
Young, Robert J. https://orcid.org/0000-0001-7003-3017
Schöder, Heiko https://orcid.org/0000-0002-5170-4185
Gutin, Philip H. https://orcid.org/0000-0003-2864-6279
Bander, Neil H. https://orcid.org/0000-0003-4642-0759
Osborne, Joseph R. https://orcid.org/0000-0003-0232-5960
- License Information
-
More Information
Article History
Received: 3 August 2021
Accepted: 24 August 2021
First Online: 8 September 2021
Change Date: 10 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-022-05736-6
Declarations
:
: All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed written consent was obtained from all individual participants included in the study.
: C.G. reports consulting for BTG International, ONO, Kite, and ROCHE. M.R.M. is a co-inventor of intellectual property licensed by MSK to Actinium Pharmaceuticals and Y-mAbs Therapeutics and is a consultant for Crinetics. J.A.D. reports consulting for Janssen Research & Development and Invicro. R.J.Y. reports consulting for Agios, Puma, NordicNeuroLab, and ICON plc, and has received research support from Agios. N.H.B. is an inventor on patents for anti-PSMA antibody technology that are assigned to Cornell University, receives consulting fees from and owns equity in Convergent Therapeutics (the company that Cornell University licensed the patents to for further R&D), is a SAB member (uncompensated), owns equity in Telix Pharmaceuticals (developing J591-Lu<sup>177</sup>), and serves as a SAB member (compensated) for Aikido Pharma. The remaining authors report no competing interests.
